Fulcrum Therapeutics Signs an Exclusive Worldwide License Agreement with GSK to Develop and Commercialize Losmapimod for Facioscapulohumeral Muscular Dystrophy

Shots:

• GSK to receive shares of Fulcrum’s preferred stock, milestones & royalties on sales of losmapimod. Fulcrum to get exclusive WW rights to develop & commercialize of losmapimod with all patent rights
• Fulcrum has conducted pre-clinical testing of losmapimod and identified it as potent regulator of DUX4 gene. In mid-2019, Fulcrum plans for the onset of P-IIb trial of losmapimod in patients with FSHD across multiple sites in the US and Europe
• Losmapimod is a selective p38α/β mitogen activated protein kinase (MAPK) inhibitor, evaluated in 3,500 candidates for multiple indication in 24 clinical studies

Click here to read full press release/ article | Ref: Fulcrum Therapeutics | Image: MT2G